CHAC technology

CELLBOOSTER®


# CLINICAL EVIDENCE

CELLBOOSTER® LIFT CELLBOOSTER® GLOW CELLBOOSTER® HAIR

suisselle

beauty ▪ science ▪ innovation

CE 0373

CELLBOOSTER®

# CHAC TECHNOLOGY

**CHAC Technology** modifies and exploits the natural properties of Hyaluronic Acid (HA) making it an **optimal vehicle** for transporting essential nutrients to the skin, ensuring their **effective delivery** and **long-lasting results.**

This proprietary technology makes it possible to integrate biologically active ingredients onto HA macromolecules under conditions of mechano-stimulated reactions - **simultaneous pressure** and **shear deformation.** Specific bioactive components such as vitamins, and amino acids are **simultaneously integrated** and **uniformly distributed** onto the HA macro chains, **forming a large complex** that in essence represents a **unique macromolecular 'depot'** of biologically active material. As a result, multiple molecular complexes are formed.

These **molecular complexes** are based on supramolecular interaction between bioactive components and functional groups of HA, and unlike bioactive components **cannot be recognized by hyaluronidase.**




## STEP 1

### FORMING OF A HA MATRIX:

**High pressure** and **shear deformation** ensures unfolding of the molecules of HA.

## STEP 2

### FORMING OF LINKED COMPLEX:

**Integration of active components** into the structure of the HA "matrix" under the influence of pressure and shear deformation with **the formation of links** between HA molecules and active components (amino acids and vitamins).

## STEP 3

### FORMING THREE-DIMENSIONAL STRUCTURAL CHAC-COMPLEX:

The pressure on molecules reduces resulting in "unfolding" of the HA molecules with **integrated active components.**

CHAC technology

# CELLBOOSTER®

# LIFT


# CLINICAL STUDY

A prospective, open study on the safety and effectiveness of CELLBOOSTER® LIFT (stabilized booster complex using CHAC technology) on healthy subjects.
Study conducted by EUROFINS in collaboration with Dr. Patricia Morel Mandrino (France) and Dr. Gabriel Siquier (Spain).
*Study led by Eurofins, independent laboratory (France).*

suisselle
beauty ▪ science ▪ innovation

CE 0373

CELLBOOSTER® LIFT

# CLINICAL STUDY

## INDICATIONS:

- Moderate skin depression, loss of firmness or laxity (facial tissue & contours)
- Fine lines & wrinkles
- Dehydrated skin
- Visible dryness
- Loss of skin tone & microcirculation
- Atrophic scars, post acne, striae
- Couperose.

## TREATMENT AREAS:

Epidermis and dermis of:

- Face
- Neck
- Decollete area
- Back of the hands
- Internal face of the arms
- Body

- ✓ Lifts & Smoothes Wrinkles
- ✓ Skin Redensification
- ✓ Skin Tone & Microcirculation Improvement

## COMPOSITION:

Stabilized
HYALURONIC ACID 18 mg

VITAMINS
- Riboflavin (B2)
- Sodium Ascobyl Phosphate (C)
- Tocopherol (E)
- Biotin


AMINO ACIDS
- Arginine
- Glycine
- Lysine
- Proline
- Valine

STABILIZED REJUVENATING COMPLEX

## METHODOLOGY:

### Study design:

Prospective, monocentric, open, non comparative, post-marketing study designed to investigate the efficacy and safety of CELLBOOSTER® Lift on healthy female and male subjects (n=41) aged between 36 and 55 years old, with signs of cutaneous dryness on cheekbones and cutaneous aging on the face (wrinkles, skin laxity and dull skin).

### Patient treatments and follow-up




- EMLA CREAM 5%
- 3ml CELLBOOSTER Lift / Session
- Intradermal injection (papula)
- Same injection technique and depth for every patients (whole face excepted forehead)

### Patient inclusion & disposition

✓ 41 healthy patients aged from 36 to 55 years old (mean 47.8 ± 4.95 yrs, 37 female and 4 male subjects) were included in the study to receive injections of CELLBOOSTER® Lift.

✓ All subjects included had hydration values (measured by Corneometer® at baseline) <60AU (mean ± SD = 44.81 ± 8.66 AU).

### Objectives:

Primary:
- To evaluate CELLBOOSTER® Lift **effectiveness on skin hydration improvement** 2 weeks after the last treatment (considering a clinically relevant improvement with a change from baseline higher than 2 AU).

Secundary:
- To evaluate **effectiveness on the improvement of skin quality** by objective measurement of skin biomechanical parameters, density, hydration, microcirculation, wrinkles and colour, 2 and 8 weeks after the last treatment.
- To evaluate **effectiveness on clinical Global Aesthetic Improvement**, using the Global Aesthetic Improvement Scale (GAIS), **evaluated by the investigator** 2 and 8 weeks after the last treatment.
- To evaluate **effectiveness on clinical Global Aesthetic Improvement**, using the GAIS, **evaluated by the subject** 2 and 8 weeks after the last treatment.
- To evaluate the **satisfaction of the injectors and the subjects** using a subjective evaluation questionnaire 2 and 8 weeks after the last treatment.
- To illustrate **aesthetic effect through 2D photography** throughout the study period.
- To evaluate **safety throughout the study period by Injection Site Reactions (ISRs) and adverse events (AEs)** collection.

### Assessments/endpoints

Primary:

Moisture *(corneometer)* — Change from baseline of epidermis hydration (>2AU*) at D42 — *Arbitrary Unit.

**Functional measures**

Secondary:
- Hydration *(corneometer)*
- Skin microcirculation *(Laser Doppler)*
- Skin parameters *(cutometer)*
- Skin density *(Dermascan)*
- Skin color *(photographies)*
- Skin wrinkles parameters *(Fringe projection system)*

Change at D42/84 vs. baseline

**Subjective measures**
- Aesthetic effect *(photographies)*
- GAIS score ≥ "improved" *(investigator & subjects)*
- Degree of satisfaction *(subjective questionnaire – Investigator & subjects)*

**Safety** — Injection site reactions (ISRs) and adverse events (AEs) collection – Investigator & subjects

### Statistical analyses & populations

- FAS (Full Analysis Set): n=41 (any subject included in the study with at least a post-basal value)
- PP (Per Protocol) population: n=39 (any subject included in the study without major deviation)
- Safety population: n=41 (any subject having used the tested device).

CELLBOOSTER® LIFT

# RESULTS AT D42

## A significant improvement in skin density

Skin density change *(Dermascan)*

**Changes in skin density value between D42 and baseline**




*More rejuvenated cells such as fibroblasts => working the skin from the inside!*

**Significant increase in the proportion of echogenic signal (+0.06, +30%) 2 weeks after the last injection**

## A significant improvement in skin microcirculation

Skin microcirculation *Laser Doppler*

**A significant improvement in skin microcirculation and capillary flux**




*A better blood flow, and thus more oxygen & energy for the tissue!*

**Significant increase in skin microcirculation (perfusion units & capillary flux by >15 units (>37%)) 2 weeks after the last injection**

## A significant improvement in skin hydration (primary endpoint)

Moisture change *(Corneometer®)*

**A significant improvement in skin moisture/hydration 2 weeks after the last injection**

**Changes in hydration value between D42 and baseline**




**The improvement of skin hydration was statistically superior from 2 (p=0.0286) at D42 (2 weeks after the last injection), which indicates the efficacy of the treatment**

## A significant improvement in skin viscoelasticity parameter

Viscoelasticity change *(Cutometer®)*

**A significant improvement in skin viscoelasticity 2 weeks after the last injection**

**Changes in skin viscoelasticity value between D42 and baseline**




**Statistically significant increase (+12.5%) in skin viscoelasticity (p=0.0038) two weeks after the last injection**

CELLBOOSTER® LIFT

# RESULTS AT D42

## A significant improvement in aesthetic rating

### A significant improvement in skin microcirculation and capillary flux

**Aesthetic change - GAIS**
as measured by investigators and subjects




**Responders rates**
as measured by investigators and subjects




A very high satisfaction and a statistically significant responder rate as rated by the investigators and the subjects 2 weeks after the last injection

## CELLBOOSTER® Lift: a significant improvement in aesthetic rating

### Very high satisfaction rates among included patients

### Patient satisfaction and agreement regarding the improvement of their skin




A very high satisfaction of the subjects 2 weeks after the last injection

### Subject Satisfaction

**>90%** HIGH or VERY HIGH Patients SATISFACTION!

*« The treatment is good »*
*« Obtained results »*

**>60%** Patients SATISFACTION on all parameters!

*« Hydrated skin »*
*« Firmer skin »*

CELLBOOSTER® LIFT



## A high satisfaction during injection sessions

Injectors appraisal on product features
during the 3 injections

100% HIGH or VERY HIGH SATISFACTION at D0, D14 & D28!

- ✓ EASE OF INJECTION
- ✓ EASE OF VIAL MANIPULATION
- ✓ EASE OF PRODUCT POSITIONING
- ✓ EASE OF TURBIDITY DETECTION

## CELLBOOSTER® Lift: Injection Site Reactions (ISRs) and Adverse Events (AEs) appraisal

Injection site reactions* as reported by the investigators and the subjects

**Safety endpoint - ISRs**
**Investigators and subject report**
*(ISRs collection)*

Proportion of patients presenting at least one sign of ISR during the clinical trial




- ✓ Most of the ISRs observed by the investigators and subjects were judged as being mild.
- ✓ None of the reported ISRs were considered as severe whatever the injection point.
- ✓ All ISRs reported by the subjects lasted from 1 to 3 days & disappeared 2 weeks after each injection session.

**ISRs were considered as expected following an injection with a Class III medical device & resolved 2 weeks after the last injection**

* ISRs reported by investigators and subjects were considered as expected after a Class III medical device injection and included Redness/Erythema, Pain/tenderness, Induration, Oedema, Lumps/Bumps, Bruising/Hematoma, Itching and Discoloration/Pigmentation.

CELLBOOSTER® LIFT

# CONCLUSION

**A strong clinical trial that allows 2 weeks after a 3 injections protocol to observe that CELLBOOSTER® LIFT leads to:**

**+37.6%**
SKIN MICROCIRCULATION

**+12.5%**
SKIN VISCOELASTICITY

**+29.2%**
SKIN DENSITY


**+12.4%**
SKIN HYDRATION

**+100%**
HIGH OR VERY HIGH
INJECTORS SATISFACTION

**>90%**
HIGH OR VERY HIGH
PATIENTS SATISFACTION

**With a well tolerated treatment**

CHAC technology

# CELLBOOSTER®

# GLOW


# HUMAN SKIN EXPLANTS STUDY

Anti-Aging and Depigmentation Effect of a Hyaluronic Acid Mechanically Stabilized Complex on Human Skin Explants.

Gabriel Siquier-Dameto, Sylvie Boisnic, Pere Boadas-Vaello and Enrique Verdú.

*Study Led by Gredeco, independent laboratory (France).*

suisselle
beauty ▪ science ▪ innovation

CE 0373

CELLBOOSTER® GLOW

# HUMAN SKIN EXPLANTS STUDY

Independent study conducted by GREDECO Laboratory (France), led Dr. Sylvie Boisnic to demonstrate the **depigmenting** and **anti-aging efficacy** of CELLBOOSTER® Glow injected into the dermis of human skin maintained in survival.

## COMPOSITION:

Stabilized HYALURONIC ACID 18mg

VITAMINS

- Sodium Ascorbyl Phosphate (C)
- Biotin


AMINO-ACIDS

- Cysteine
- Glutathione
- Glycine
- Lysine
- Proline
- Valine

STABILIZED REVITALIZING COMPLEX

## METHODOLOGY:

In the present study, skin samples from four female donors between 29 and 57 years of age have been used.
**The depigmenting effect** was analyzed on native skin after 12 days.
For this purpose, CELLBOOSTER® Glow injections were performed at D0 in the superficial dermis and the upper part of the middle dermis.
The 2 following conditions were compared in duplicate for each donor: control skin *versus* CELLBOOSTER® Glow.

**The anti-ageing effect** of the products was analyzed in a UV ageing model.
For this purpose, an oxidative stress with UVA and UVB doses was carried out at D0.
After UV session, CELLBOOSTER® Glow injections were performed in the superficial dermis and the upper part of the middle dermis.
For anti-aging effect, 2 series of culture were made at D4 (MMP1 analysis, GAGs assay) and D12 (procollagen and elastin).
The 3 following conditions were compared in duplicate for each donor: control skin *versus* UV versus UV + CELLBOOSTER® Glow.

## CONCLUSION:

In an experimental aging model by ultraviolet (UV) on human skin maintained in survival condition, an anti-ageing effect was obtained after injection of CELLBOOSTER® Glow with an increase of **47.9% pro-collagen type I,** 25.3% elastin and 22.4% sulfated Glycosaminoglycannes (GAGs).
Depigmenting effect of CELLBOOSTER® Glow was also shown with a significant decrease of cell number with important pigmentation.



GREDECO

Histogram of the percentage of cells with low (score 1), medium (score 2) and high (score 3) melanin content in both experimental groups (Control, CBG). Values are mean ± standard deviation (n = 8 values). * p < 0.05 compared to the control group.

## Melanic pigment (Fontana Masson staining)




## Fontana staining x 400



Control skin 1



Skin 1 after injection with CELLBOOSTER® Glow



Control skin 2



Skin 2 after injection with CELLBOOSTER® Glow

## Pro-collagen type I assay




After injection of CELLBOOSTER® Glow, a significant increase of pro-collagen type I by 47.9% was obtained in comparison with UV condition.

## Elastin assay




The elastin synthesis is significantly increased by 25.3% after injection of CELLBOOSTER® Glow in comparison with UV condition.

## Sulfated | glycosaminoglycans assay




After injection of CELLBOOSTER® Glow, a significant increase of sulfated glycosaminoglycans by 22.4% was obtained in comparison with UV condition.

GREDECO

CELLBOOSTER® GLOW

# Discover the full scientific article published in the renowned Polymers Journal: Anti-Aging and Depigmentation Effect of a Hyaluronic Acid Mechanically Stabilized Complex on Human Skin Explants by Gabriel Siquier-Dameto, Sylvie Boisnic, Pere Boadas-Vaello and Enrique Verdú.

polymers

NEW ARTICLE

Anti-Aging and Depigmentatio Effect of a Hyaluronic Acid Mechanically Stabilized Complex on Human Skin Explants

polymers

MDPI

Article

Anti-Aging and Depigmentation Effect of a Hyaluronic Acid Mechanically Stabilized Complex on Human Skin Explants

Gabriel Siquier-Dameto †,‡, Sylvie Boisnic *,†, Pere Boadas-Vaello † and Enrique Verdú †,*

CHAC technology

# CELLBOOSTER®

# HAIR


# CLINICAL TRIAL

Results of the clinical trial on 26 healthy subjects treated with CELLBOOSTER® HAIR (stabilized booster complex using CHAC technology).
Fighting hair loss & Strengthening hair follicles to improve hair density and quality.
*Trial led by Gredeco, independent laboratory (France).*

suisselle
beauty ▪ science ▪ innovation

CE 0373

CELLBOOSTER® HAIR

# CLINICAL TRIAL

## INDICATIONS:

- Non cicatricial alopecia,
- Alopecia areata,
- Androgenic alopecia,
- Damaged hair shaft (brittle, dull color, split ends),
- Premature graying,
- Seborrhea, psoriasis.

## TREATMENT AREAS:

Epidermis and dermis of the scalp (near hair roots according to the mesotherapy applied technique).

## COMPOSITION:

HYALURONIC ACID 18 mg

VITAMINS
- Niacin
- Pantothenic Acid (B5)
- Pyridoxine (B6)
- Biotin (B7)
- Cyanocobalamin (B12)
- Rutin


AMINO ACIDS
- Arginine
- Cysteine
- Glutamine
- Glycine
- Lysine

COPPER

ZINC

**STABILIZED REJUVENATING COMPLEX**

CHAC technology

- ✓ Nourishes the scalp and fortifies follicles,
- ✓ Accelerates hair growth,
- ✓ Prevents hair loss and graying.

## METHODOLOGY:

### Study purpose:

The objective of this study was to clinically assess the effect on hair density and hair quality after 6 sessions of CELLBOOSTER® HAIR injections on 26 healthy subjects, equally shared between men and women.

### Patient treatments and follow-up & assessments






- 3 ml of Cellbooster® Hair.
- Injection by micro-papula technique.
- At least 50 injection points.

## ASSESSMENTS:

### Hair quality clinical analysis:

- ✓ Thickness
- ✓ Shine
- ✓ Hair loss

### Hair density & thickness improvement:

- ✓ Scoring on macrophotography with Proscope x30

### Hair shine

- ✓ Measurement with Glossymeter

### Effect of the product:

- ✓ Scalp photographies by LifeViz 2D mini®

### Subject satisfaction (self assessment) and GAIS (global aesthetic improvement scale)

### Tolerance:

- ✓ Check of the absence of undesirable events at each visit.
- ✓ Each adverse event was reported within 48 hours and was included in the study report.

CELLBOOSTER® HAIR

# CLINICAL TRIAL

## INCLUSION CRITERIA

### General criteria:

- Subjects able to follow the trial procedures.
- Subjects giving their free and written consent after oral and written information about the study.

### Specific criteria:

- Women or men, age over 18 years old.
- For men, qualification by the Norwood-Hamilton scale: class 2a, 3, 3a or 3a vertex.

**Norwood-Hamilton scale**




- For women, qualification by the Ludwig scale: type 1 or 2

**Ludwig scale**




- Women agreed to perform a pregnancy test (for women who can procreate a pregnancy test will be performed before each injection).
- Low to moderate capillary density.
- Subject not using care (topical or systemic) intended for hair growth/improvement.
- Subject agreeing not to be exposed to the sun for the duration of the study.

## PRINCIPAL EXCLUSION CRITERIA - SUBJECTS WITH:

### General criteria:

- Currently participating in another clinical study related to pharmaceuticals or medical devices or subject in a period of exclusion from a clinical study.
- Facial injections/implants of any non-absorbable filler in his or her lifetime.
- Pregnant or lactating woman.
- Often exposed to the sun or UV during the last 15 days.

### Allergies & inflammatory condition or other risk of infections:

- History of multiple severe allergies or anaphylactic shock.
- Known hypersensitivity to hyaluronic acid or to chlorhexidine.
- Tendency to develop inflammatory skin reactions or hypertrophic scars.
- An inflammatory skin reaction on or near the area to be treated (according to the opinion of the investigator).
- History of streptococcal disease (recurrent angina, rheumatic fever).
- Skin pathology, or an acute inflammatory reaction or bacterial or viral infection, at the study area level, or seen 6 weeks after the end of such an episode.
- Epilepsy not controlled by treatment.
- General pathology, skin pathology, dermatosis, acute or chronic systemic disease, and/or taking general or topical treatment that in the opinion of the investigator may interfere with the treatment or compromise the subject's participation in the study.
- Dermatological diseases that can reach the scalp (for example: pelade or lichen planus).
- Endocrine disruption mainly affecting the thyroid and more specifically hypothyroidism.

### Concomitant treatments:

- Oral/injectable corticosteroid (or not stopped for ≥ 3 months). Inhaled corticosteroids are allowed as well as topical corticosteroid therapy not involving study areas.
- Concomitant treatment (or not stopped for ≥ 1 year) of immunosuppressant or chemotherapy - A history of less than 12 months of radiation therapy at the study area level or of autoimmune pathology or connective tissue.
- Aspirin or anti-coagulants in regular doses during the past 15 days.

CELLBOOSTER® HAIR

# CLINICAL EVALUATION RESULTS

## 3 weeks after the injection protocol (6 treatments)



### CELLBOOSTER® Hair: for more hair strenght and resistance

Clinical evaluation

Changes in hair thickness before, during and after the injection protocol (6 treatments)




A continuous & additive improvement in hair STRENGHT after injections of CELLBOOSTER® Hair with a more and more SIGNIFICANT & beneficial effect

### CELLBOOSTER® Hair: for significantly less loss

Clinical evaluation

Changes of hair loss assessed by clinical score by the subjects




CELLBOOSTER® Hair for a SIGNIFICANT reduction of hair loss
After 3 injections and even more after a full protocol of 6 injections

### CELLBOOSTER® Hair: for shiny hair

Clinical evaluation

Changes of hair shine assessed by clinical score by the subjects




CELLBOOSTER® Hair for more shiny and beautiful hair with a SIGNIFICANT benefit after 6 injections

** Not significant*
*Statistical analyses were performed with the Friedman test.*

CELLBOOSTER® HAIR

# BIOMETRIC EVALUATION RESULTS

## 3 weeks after the injection protocol (6 treatments)

### CELLBOOSTER® Hair: a confirmation of the improvement of hair thickness by Proscope X30

Macrophotography

Changes of hair thickness assessed by Proscope X30




A biometric confirmation of hair THICKNESS improvement with CELLBOOSTER® Hair with a SIGNIFICANT benefit after a full protocol (6 injections)

### CELLBOOSTER® Hair: for more density

Macrophotography (Proscope X30)

Changes of hair density assessed by Proscope X30




**CELLBOOSTER® Hair for more DENSITY of the hair in all assessed areas** (posterior & middle central line, vertex, occiput, left & right temple) **with a SIGNIFICANT benefit after 3 injections and an even more pronounced effect after a full protocol (6 injections)**

### CELLBOOSTER® Hair: a confirmation of the improvement of hair shine by glossymeter

Biometric assessment (glossymeter)

Changes of hair shine assessed by glossymeter




A biometric confirmation of hair SHINE improvement with CELLBOOSTER® Hair with a SIGNIFICANT benefit after a full protocol (6 injections)

** Not significant*
*Statistical analyses were performed with the Friedman test.*

CELLBOOSTER® HAIR

# A very high satisfaction of the subjects regarding the benefits of CELLBOOSTER® Hair

**96%**
"MY HAIR CONDITION IS GLOBALLY IMPROVED"

**88%**
"MY HAIR LOSS IS REDUCED"

**88%**
"MY HAIR IS DENSER"

**84%**
"MY HAIR IS THICKER

**77%**
"MY HAIR IS SHINIER"

**65%**
"MY HAIR GROWTHS BACK FASTER"

**(% of patients who "completely agree" or "rather agree" on quality of their hair – answer gathered with a self questionnaire)*

D0 D90



D40 D90

D0 D90



D0 D90

CELLBOOSTER® HAIR

# A very high satisfaction of the subjects regarding the benefits of CELLBOOSTER® Hair

D0 D90



D0 D90



D0 D90



D0 D90



**88%**

"I WOULD RECOMMEND THE TREATMENT TO MY FRIENDS"

CELLBOOSTER® HAIR

# CONCLUSION

## Results 3 weeks after the injection protocol (6 treatments)

**A strong clinical trial that allows 3 weeks after a 6 injections protocol to observe that CELLBOOSTER® Hair leads to:**

### Clinical evaluation

**+37.5%**
THICKNESS

**-54.9%**
LOSS

**+32.6%**
SHINE

### Biometric assessments

**+9.4%**
THICKNESS

**+26%**
DENSITY

**+38.7%**
SHINE

CELLBOOSTER® HAIR

# CONCLUSION

## Results 3 weeks after the injection protocol (6 treatments)

## A very high patient satisfaction

**9** PATIENTS OUT OF 10 — Found their hair at least improved to very much improved.

**+88.4%** — Find an improvement of the hair density.

**+88.6%** — Find a slow down in hair loss.

**+84.7%** — Find their hair thicker.

With a **dermatological tolerance** that was judged by the investigators as being **Excellent for the 26 patients.**

suisse

# CELLBOOSTER®

CELLBOOSTER® is a **Swiss made injectabl**
Four unique stabilized complexes composed of

NO CHEMICAL BINDING AGENTS • SAFE & MAJOR SIDE EFFECT RISK DIMINISHED

SLOW RELEASE OF ACTIVE INGREDIENTS • EFFE RESU

## LIFT


- Moderate skin depressions, loss of firmness in factial tissues & contours
- Loss of skin tone & microcirculation
- Couperose, atrophic scars, post-acne, striae
- Dehydrated skin, fine lines, wrinkles

## GLOW


- Hyperpigmentation.
- Uneven skin tone
- Sun-damaged and enviroment compromised skin
- First sign of ageing, fine lines, wrinkles
- Dry skin.

### STABILIZED REJUVENATING COMPLEX

CHAC Technology

- HYALURONIC ACID 18mg (6mg/ml)
- Amino acids: ARGININE, GLYCINE, LYSINE, PROLINE, VALINE
- Vitamins: RIBOFLAVIN (B2), SODIUM ASCORBYL PHOSPHATE (C), TOCOPHEROL (E), BIOTIN

### STABILIZED REVITALIZING COMPLEX

CHAC Technology

- HYALURONIC ACID 18mg (6mg/ml)
- Amino acids: CYSTEINE, GLUTATHIONE, GLYCINE, LYSINE, PROLINE, VALINE
- Vitamins: SODIUM ASCORBYL PHOSPHATE (C), BIOTIN

Intensive course:

3 treatments with 2-3 weeks interval

Support course:

1 treatment per month

suisselle

# R® AT A GLANCE

**ctable boosters (Class III Medical Device).**
ed of hyaluronic acid, amino acids, and vitamins:

- EFFECTIVE & LONG-LASTING RESULTS

UNIQUE COMPLEX INGREDIENTS COMBINATION

- COVERS MULTIPLE INDICATIONS WITH ONE PRODUCT
- CELLBOOSTER® PRODUCTS CAN BE COMBINED IN THE SAME TREATMENT

## SHAPE


- Local fat accumulation
- Double chin
- Cellulite
- Puffiness, edema
- Cheeks & eye bags
- Sagging skin

## HAIR


- Non cicatricial alopecia
- Alopecia areata
- Damaged hair shaft (brittle, dull color, split ends)
- Premature graying
- Seborrhea, psoriasis

### STABILIZED RESHAPING COMPLEX

CHAC Technology

- HYALURONIC ACID 18mg (6mg/ml)
- Amino acids: L-CARNITINE
- Vitamins: SODIUM ASCORBYL PHOSPHATE (C)

### STABILIZED STRENGTHENING COMPLEX

CHAC Technology

- HYALURONIC ACID 18mg (6mg/ml)
- Amino acids: ARGININE, CYSTEINE, GLUTAMINE, GLYCINE, LYSINE
- Vitamins: NIACIN, PANTOTHENIC ACID (B5), PYRIDOXINE (B6), BIOTIN (B7), CYANOCOBALAMIN (B12), RUTIN
- Copper Gluconate, Zinc carbonate

Intensive course:



6 treatments with 2-3 weeks interval

Support course:

1 treatment per month

suisselle

beauty ▪ science ▪ innovation

Rue Galilée 6 | 1400 Yverdon-les-Bains | Switzerland

www.suisselle.com | info@suisselle.com

Suisselle Global @suisselle.pro